UCB’s corporate venture capital unit has helped the antiviral treatment developer close its series A round, joining a $22.6m extension.
Belgium-based antibody therapy developer ExeVir Bio has closed its series A round at $50m with a $22.6m extension featuring UCB Ventures, the corporate venturing subsidiary of pharmaceutical firm UCB.
Venture capital firm Fund+ led the tranche, which included life sciences research organisation VIB and its V-Bio Ventures affiliate as well as SFPI-FPIM, SRIW, Noshaq, Vives Inter-University Fund, SambrInvest and unnamed Belgian family offices.
Spun off from VIB, ExeVir Bio is developing antibody-based therapies to treat and protect against viral infections.…
